This is the first long-term follow-up of a clinical trial assessing an additive treatment for stomach cancer consisting of a fully human IgM antibody directed specifically against the tumour-specific CD55PAT-SC1 variant of CD55. Here, CD40LG is linked to gastric neoplasm.